US · KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Kirkland, WA 98033
- Website
- kestramedical.com
Price · as of 2025-04-30
$21.82
Market cap 1.36B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $38.86 | +78.09% |
| Intrinsic Value(DCF) | $89.09 | +308.3% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | $0.00 | $0.00 | |||
| 2025 | $14.91 | $38.86 | $1.74 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates KESTRA MEDICAL TECHNOLOGIES, LTD.'s (KMTS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $38.86
- Current price
- $21.82
- AI upside
- +78.09%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$89.09
+308.3% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $21.82 | 1.36B | +78% | +308% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| AZTA | Azenta, Inc. | $26.98 | 1.24B | +62% | -42% | -40% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| BLFS | BioLife Solutions, Inc. | $24.20 | 1.17B | +49% | -55% | -73% | — | — | 2.89 | 11.18 | -103.07 | — | 2.89 | 64.56% | -12.61% | -12.61% | 0.00% | -4.52% | 0.00% | 0.03 | -4.48 | 5.23 | 5.23 | -1.18 | -4318.00% | 1697.00% | 28653.00% | 1.87% | 0.88 | 7.49% | 0.00% | — | 0.00% | -79.66 | 48.04 | 10.04 | 18.23 |
| EVO | Evotec SE | $3.40 | 1.21B | +721% | -44% | — | — | -5.60 | 1.15 | 1.38 | -14.20 | -3.91 | 1.71 | 14.41% | -17.88% | -24.60% | -18.92% | -12.23% | -9.42% | 0.47 | -12.18 | 1.98 | 1.79 | -1.70 | 14348.00% | 199.00% | -3650.00% | -10.38% | 0.05 | -9.79% | 0.00% | 0.00% | 15.22% | -8.04 | -10.05 | 1.44 | 0.58 |
| NEOG | Neogen Corporation | $11.23 | 2.44B | +204% | -82% | — | — | -1.01 | 0.53 | 1.23 | -2.01 | -0.01 | -2.73 | 47.10% | 1.05% | -122.06% | -41.88% | 0.27% | -27.33% | 0.44 | 0.13 | 3.32 | 1.62 | -0.84 | 1146322.00% | -320.00% | -3914.00% | -4.21% | 0.33 | -1.38% | 0.00% | 0.00% | 0.00% | 200.15 | -40.68 | 2.11 | 0.67 |
| NVCR | NovoCure Limited | $13.67 | 1.53B | +107% | -55% | — | — | -11.06 | 4.43 | 2.30 | -11.25 | — | 4.43 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -2179.00% | 828.00% | 932.00% | -5.02% | -0.22 | -58.98% | 0.00% | 0.00% | 22.09% | -8.71 | -17.70 | 2.04 | 0.52 |
| PGEN | Precigen, Inc. | $3.79 | 1.14B | +633% | -73% | — | +239% | -3.94 | 12.93 | 126.87 | -3.28 | -19.23 | 33.38 | -8.71% | -3440.23% | -3216.18% | -160.80% | -3010.47% | -85.20% | 0.14 | -22504.83 | 4.76 | 4.60 | 0.19 | 2051.00% | -3695.00% | 1211.00% | -15.41% | -3.17 | -1735.60% | 0.00% | 0.00% | 4.73% | -3.00 | -5.28 | 103.33 | -19.72 |
| PLSE | Pulse Biosciences, Inc. | $18.73 | 1.27B | — | — | — | — | -17.46 | 15.75 | 3629.72 | -16.69 | -100.37 | 16.44 | -360.00% | -21982.57% | -20794.57% | -74.45% | -1168.13% | -63.68% | 0.09 | — | 10.53 | 10.22 | 1.02 | 1739.00% | — | 4927.00% | -4.29% | -6.83 | -826.49% | 0.00% | 0.00% | 0.00% | -15.56 | -21.99 | 3420.56 | 40.87 |
| STAA | STAAR Surgical Company | $19.90 | 982.38M | +92% | -59% | -70% | — | -44.58 | 2.27 | 2.87 | -123.99 | — | 2.28 | 76.32% | -4.02% | -6.44% | -5.16% | -6.20% | -4.05% | 0.10 | — | 5.23 | 4.41 | 18.43 | -19535.00% | -264.00% | 11338.00% | -0.85% | 0.22 | -3.77% | 0.00% | 0.00% | 0.17% | -56.24 | -92.48 | 2.26 | 5.87 |
| TERN | Terns Pharmaceuticals, In… | $42.12 | 3.79B | — | — | — | — | -3.12 | 0.80 | — | 0.79 | — | 0.80 | 0.00% | — | — | -29.56% | 1106.27% | -28.10% | 0.00 | — | 23.14 | 22.89 | 1.59 | -1181.00% | — | 388.00% | -25.25% | -4.47 | 760.80% | 0.00% | 0.00% | 29.11% | 0.78 | 1.13 | — | 7.82 |
| WVE | Wave Life Sciences Ltd. | $13.93 | 2.59B | +134% | -54% | — | +334% | -11.43 | 4.51 | 54.67 | -8.57 | -15.69 | 4.51 | 0.00% | -504.09% | -478.33% | -56.16% | 323.63% | -108.74% | 0.03 | — | 6.47 | 6.35 | 2.86 | 7286.00% | -6055.00% | 2338.00% | -8.03% | -1.97 | 281.72% | 0.00% | 0.00% | 13.17% | -8.13 | -9.34 | 40.99 | 1.20 |
About KESTRA MEDICAL TECHNOLOGIES, LTD.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
- CEO
- Brian Webster
- Employees
- 300
- Beta
- -0.23
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($89.09 ÷ $21.82) − 1 = +308.3% (DCF, example).